Globe and Mail (Free subscription) | 07/24/2008
Government to give 500-page Health Canada report a "low profile" release on website
Internet News (Free subscription) | 07/24/2008
The Canadian government commissions reports on climate change and then buries them. A report by Health Canada on the health impacts of climate change was promised for the spring 2008 and then on July 3rd said it would be posted...
Carbon-Based (Free subscription) | 07/24/2008
Globe and Mail (Toronto) : When Health Canada finally releases a major report on the health impacts of climate change, it will do so by posting it on the ministry website. It's an approach that was used once before on another climate change study. Then, as now, it undermined the credibility of the federal government's commitment to addressing global warming. Human Health in a Changing Climate: A Canadian...
Red Orbit (Free subscription) | 07/24/2008
Santhera Pharmaceuticals has announced that Health Canada has approved SNT-MC17/idebenone, subject to certain conditions, for the treatment of Friedreich's Ataxia. Health Canada's decision is said to be the first marketing authorization worldwide for any Friedreich's Ataxia therapy.
Market Wire - Pharmaceuticals and Biotech: Biotech (Free subscription) | 07/24/2008
LIESTAL, SWITZERLAND (MARKET WIRE) Santhera Pharmaceuticals (SWX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich's Ataxia. Health Canada's decision is the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will...
Inbox Robot: Swiss Reinsurance News (Free subscription) | 07/24/2008
In clinical studies submitted to Health Canada as part of the approval process, Catena showed statistically and clinically relevant improvements in Friedreich's Ataxia patients, ...
EuroInvestor.co.uk (Free subscription) | 07/24/2008
Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/ideben.. - Read more
Market Wire - Government: International (Free subscription) | 07/23/2008
OTTAWA, ONTARIO (MARKET WIRE) The Honourable Tony Clement, Minister of Health, today announced increased protection for Canadians with food allergies by introducing new labelling requirements for food allergens, gluten sources and added sulphites contained in prepackaged foods. Health Canada also announced the launch of several allergy studies, including a large national study of food allergy prevalence,...
Accidental Deliberations (Free subscription) | 07/23/2008
Shorter Con communication policy on a Health Canada study discussing the harmful effects of climate change which was supposed to have been released this spring: Suppress harder, dammit!
Market Wire - Government (Free subscription) | 07/23/2008
OTTAWA, ONTARIO (MARKET WIRE) Health Canada is warning consumers not to use the unauthorized product Jin Bu Huan Anodyne because it contains the undeclared ingredient tetrahydropalmatine, which has been associated with serious adverse health effects.
Globe and Mail (Free subscription) | 07/23/2008
The Conservative government is planning a quiet release for a major Health Canada report that warns of the harmful impact of climate change on the health of Canadians, particularly the young, elderly and aboriginals.
Red Orbit (Free subscription) | 07/23/2008
Health Canada is warning consumers not to use the unauthorized product Jin Bu Huan Anodyne because it contains the undeclared ingredient tetrahydropalmatine, which has been associated with serious adverse health effects.
Market Wire (Free subscription) | 07/22/2008
Globe and Mail (Free subscription) | 07/21/2008
Health Canada and the Heart and Stroke Foundation of Canada said while many fast-food restaurants have cut trans fats sharply, many soft margarine producers have resisted change
Red Orbit (Free subscription) | 07/21/2008
PharmEng International has announced that its wholly owned subsidiary, Keata Pharma, has received a site license issued by the Minister of Health under the authority of the Natural Health Products Regulations for the manufacturing, packaging and labeling of natural health products at its manufacturing facility located in Sydney, Nova Scotia.
